KR880007729A - 히루딘의 변종과 그 용도 및 그 제조방법 - Google Patents
히루딘의 변종과 그 용도 및 그 제조방법 Download PDFInfo
- Publication number
- KR880007729A KR880007729A KR870013708A KR870013708A KR880007729A KR 880007729 A KR880007729 A KR 880007729A KR 870013708 A KR870013708 A KR 870013708A KR 870013708 A KR870013708 A KR 870013708A KR 880007729 A KR880007729 A KR 880007729A
- Authority
- KR
- South Korea
- Prior art keywords
- hirudin
- glu
- gly
- asn
- variant
- Prior art date
Links
- 108010007267 Hirudins Proteins 0.000 title claims description 16
- 102000007625 Hirudins Human genes 0.000 title claims description 16
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims description 16
- 229940006607 hirudin Drugs 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- QGNXYDHVERJIAY-ACZMJKKPSA-N Asn-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGNXYDHVERJIAY-ACZMJKKPSA-N 0.000 claims 1
- UXUSHQYYQCZWET-WDSKDSINSA-N Cys-Glu-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O UXUSHQYYQCZWET-WDSKDSINSA-N 0.000 claims 1
- DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 claims 1
- OXFOKRAFNYSREH-BJDJZHNGSA-N Cys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N OXFOKRAFNYSREH-BJDJZHNGSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 claims 1
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 claims 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 claims 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 claims 1
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 claims 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 claims 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 claims 1
- AVQOSMRPITVTRB-CIUDSAMLSA-N His-Asn-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AVQOSMRPITVTRB-CIUDSAMLSA-N 0.000 claims 1
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 claims 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 claims 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 claims 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 claims 1
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 claims 1
- NLJKZUGAIIRWJN-LKXGYXEUSA-N Thr-Asp-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O NLJKZUGAIIRWJN-LKXGYXEUSA-N 0.000 claims 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 claims 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 claims 1
- 101150050575 URA3 gene Proteins 0.000 claims 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 claims 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 108010050848 glycylleucine Proteins 0.000 claims 1
- 108010010967 hirudin HV1 Proteins 0.000 claims 1
- 108010010968 hirudin HV2 Proteins 0.000 claims 1
- 108010010961 hirudin HV3 Proteins 0.000 claims 1
- 108010064235 lysylglycine Proteins 0.000 claims 1
- 101150047627 pgk gene Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Epoxy Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 설명책자들에 의해 알려진 3가지 자연성 히루딘 변종의 시 스의 비교표.
제2도는 히루딘 또는 그 변종들을 산출시키기 위한 효모균 배양물의 상징액 분량을 기준으로 한 트롬빈의 코로모자임에 대한 단백분해 활성도 억제율을 도시하는 그라프도.
Claims (13)
- 위치 47 또는 위치 63에 있어서 자연형태의 아미노산과는 단른 아미노산을 포함하는 변종.
- 제1항에 있어서, 자연형태에서 위치 63의 아미노산 Tyr이 산성 잔존물 Glu 또는 Asp로 대치되는 것을 특징으로 하는 히루딘 변종.
- 제1항 및 제2항 중 어느 하나에 있어서, 히루딘 HV1, HV2 또는 HV3의 한 변종인 것을 특징으로 하는 히루딘 변종.
- 제1항 내지 제3항 중 어느 하나에 있어서, 자연형태에서 위치 47의 아미노산이 Arg 또는 His에 의해 대치되는 것을 특징으로 하는 히루딘 변종.
- 제1항 내지 제3항 중 어느 하나에 있어서, HV2의 자연형태의 아미노산 47번인 Asn이 Lys에 의해 대치되는 것을 특징으로 하는 히루딘 변종.
- (Lys47)HV2, (Arg47)HV2, (His47)HV2, (Glu63)HV2, 및 (Asp63)HV2 등에서 선택되는 것을 특징으로 하는 히루딘 변종.
- 다음 시 스에 해당하는 히루딘 변종 :ILE THR TYR THR ASP CYS THR GLU SER GLY GLN ASN LEU CYS LEU CYS GLU GLY SER ASN VAL CYS GLY LYS GLY ASN LYS CYS ILE LEU GLY SER ASN GLY LYS GLY ASN GLN CYS VAL THR GLY GLU GLY THR PRO LYS PRO GLU SER HIS ASN ASN GLY ASP PHE GLU GLU ILE PRO GLU GLU TYR LEU GLN.
- 제1항 내지 제7항 중 어느 하나에 있어서 황산화되거나 또는 그렇지 않은 히루딘 변종.
- 트롬빈 억제제로서, 제1항 내지 제8항 중에 히루딘 변종으로 된 트롬빈 억제제.
- 항 응혈제로서, 제1항 내지 제8항 중 어느 하나에 의한 최소한 하나의 히루딘 변종을 활성성분으로서 포함하는 조성물.
- 의약제품으로서, 제1항 내지 제8항 중 어느 하나에 의한 히루딘 변종으로 된 의약제품.
- 히루딘 변종의 제조방법으로서, 합성단계, 반합성 제조단계, 및/또는 유전공학적 시행단계 등이 수반하는 것을 특징으로 하는 제1항 내지 제8항 중 어느 하나에 의한 히루딘 변종을 제조하는 방법.
- 제12항에 있어서, 플라스미드나 도는 기능적 DNA 블록으로서 사전에 혈질전환시킨 효모균의 발효로서 구성되며, 상기 플라스미드는 효모균의 2μ 플라스미드의 모사원을 포함하며 ura3 유전자를 포함하며, 대장균내의 모사원 및 항생제에 대한 저항성 마아커를 포함하며, 알파인자의 전구물체의 프리프로 시 스들은 히루딘 변종의 정보시 스의 상류에서 페이스에 맞게 융합되어 있으며, 상기 변종의 유전자의 하류에 위치하는 효모균 PGK 유전자의 전사단말을 포함하며, 상기 기능적 DNA 블록은 상기 히루딘 변종의 정보를 담고 있는 것을 특징으로 하는, 히루딘 변종의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8616723 | 1986-12-01 | ||
FR868616723A FR2607517B2 (fr) | 1986-12-01 | 1986-12-01 | Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu |
FR16723 | 1986-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880007729A true KR880007729A (ko) | 1988-08-29 |
KR960011918B1 KR960011918B1 (ko) | 1996-09-04 |
Family
ID=9341393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870013708A KR960011918B1 (ko) | 1986-12-01 | 1987-12-01 | 히루딘의 변이체와 그 용도 및 제조방법 |
Country Status (24)
Country | Link |
---|---|
US (1) | US5650301A (ko) |
EP (1) | EP0273800B1 (ko) |
JP (1) | JP2567263B2 (ko) |
KR (1) | KR960011918B1 (ko) |
AT (1) | ATE73462T1 (ko) |
AU (1) | AU617989B2 (ko) |
BG (1) | BG49719A3 (ko) |
CA (1) | CA1341416C (ko) |
CS (1) | CS276245B6 (ko) |
DE (1) | DE3777367D1 (ko) |
DK (1) | DK173247B1 (ko) |
ES (1) | ES2032465T3 (ko) |
FI (1) | FI99211C (ko) |
FR (1) | FR2607517B2 (ko) |
GR (1) | GR3004556T3 (ko) |
HU (1) | HU213871B (ko) |
IE (1) | IE60544B1 (ko) |
MC (1) | MC1884A1 (ko) |
NO (1) | NO177500C (ko) |
PL (1) | PL157254B1 (ko) |
PT (1) | PT86233B (ko) |
RO (1) | RO106890B1 (ko) |
SU (1) | SU1687032A3 (ko) |
ZA (1) | ZA879011B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2628429B1 (fr) * | 1988-03-08 | 1990-12-28 | Transgene Sa | Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir |
GB8817160D0 (en) * | 1988-07-19 | 1988-08-24 | Ciba Geigy Ag | Novel proteins |
GB8817161D0 (en) * | 1988-07-19 | 1988-08-24 | Ciba Geigy Ag | Modified proteins |
US5284768A (en) * | 1988-08-24 | 1994-02-08 | Sanofi | Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide |
FR2645175B1 (fr) * | 1989-03-31 | 1994-02-18 | Transgene Sa | Souche de saccharomyces cerevisiaeproductrice d'une proteine heterologue et procede de preparation de ladite proteine heterologue par fermentation de ladite souche |
US5879926A (en) * | 1989-03-31 | 1999-03-09 | Transgene S.A. | Yeast strains for the production of mature heterologous proteins, especially hirudin |
FR2645174B1 (fr) * | 1989-03-31 | 1994-01-07 | Transgene Sa | Souches de levure ameliorees pour la production de proteines heterologues matures en particulier d'hirudine et procede de preparation d'hirudine correspondant |
FR2646437B1 (fr) * | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
FR2656531B1 (fr) * | 1989-12-29 | 1992-04-24 | Sanofi Sa | Promoteur artificiel pour l'expression de proteines dans le levure. |
US5118790A (en) * | 1990-07-24 | 1992-06-02 | Sri International | Analogs of hirudin |
CA2072375C (en) * | 1990-11-08 | 2000-01-11 | Satoru Misawa | Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing saidvector and manufacturing method of products which is produced from said microorganism |
US5837808A (en) * | 1991-08-20 | 1998-11-17 | Baxter International Inc. | Analogs of hirudin |
US5407822A (en) * | 1991-10-02 | 1995-04-18 | Sanofi | Artificial promoter for the expression of proteins in yeast |
WO2020210965A1 (zh) * | 2019-04-16 | 2020-10-22 | 广东双骏生物科技有限公司 | 水蛭素突变体的提取纯化方法及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE78294T1 (de) * | 1984-03-27 | 1992-08-15 | Transgene Sa | Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin. |
ATE64956T1 (de) * | 1984-06-14 | 1991-07-15 | Ciba Geigy Ag | Verfahren zur herstellung von thrombininhibitoren. |
DE3429430A1 (de) * | 1984-08-10 | 1986-02-20 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens |
DE3445517C2 (de) * | 1984-12-13 | 1993-11-18 | Ciba Geigy | Für ein Hirudin-ähnliches Protein codierende DNA-Sequenz und Verfahren zur Herstellung eines Hirudin-ähnlichen Proteins |
FR2593518B1 (fr) * | 1985-05-02 | 1989-09-08 | Transgene Sa | Vecteurs d'expression et de secretion de l'hirudine par les levures transformees |
EP0209061B1 (de) * | 1985-07-17 | 1994-01-12 | Hoechst Aktiengesellschaft | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel |
-
1986
- 1986-12-01 FR FR868616723A patent/FR2607517B2/fr not_active Expired
-
1987
- 1987-11-25 NO NO874905A patent/NO177500C/no not_active IP Right Cessation
- 1987-11-27 PT PT86233A patent/PT86233B/pt unknown
- 1987-11-27 AU AU81880/87A patent/AU617989B2/en not_active Expired
- 1987-11-27 IE IE323987A patent/IE60544B1/en not_active IP Right Cessation
- 1987-11-30 CA CA000553153A patent/CA1341416C/fr not_active Expired - Fee Related
- 1987-11-30 EP EP87402696A patent/EP0273800B1/fr not_active Expired - Lifetime
- 1987-11-30 DK DK198706276A patent/DK173247B1/da not_active IP Right Cessation
- 1987-11-30 RO RO130679A patent/RO106890B1/ro unknown
- 1987-11-30 SU SU874203831A patent/SU1687032A3/ru active
- 1987-11-30 AT AT87402696T patent/ATE73462T1/de not_active IP Right Cessation
- 1987-11-30 DE DE8787402696T patent/DE3777367D1/de not_active Expired - Lifetime
- 1987-11-30 ES ES198787402696T patent/ES2032465T3/es not_active Expired - Lifetime
- 1987-12-01 JP JP62305504A patent/JP2567263B2/ja not_active Expired - Lifetime
- 1987-12-01 MC MC871932A patent/MC1884A1/xx unknown
- 1987-12-01 HU HU875394A patent/HU213871B/hu unknown
- 1987-12-01 ZA ZA879011A patent/ZA879011B/xx unknown
- 1987-12-01 PL PL1987269164A patent/PL157254B1/pl unknown
- 1987-12-01 CS CS878732A patent/CS276245B6/cs not_active IP Right Cessation
- 1987-12-01 BG BG82035A patent/BG49719A3/xx unknown
- 1987-12-01 FI FI875295A patent/FI99211C/fi not_active IP Right Cessation
- 1987-12-01 KR KR1019870013708A patent/KR960011918B1/ko not_active IP Right Cessation
-
1992
- 1992-05-12 GR GR920400903T patent/GR3004556T3/el unknown
-
1995
- 1995-06-07 US US08/480,511 patent/US5650301A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880007729A (ko) | 히루딘의 변종과 그 용도 및 그 제조방법 | |
FI953378A (fi) | Sytokiiniä pidättävät aineet | |
HUP0000302A2 (hu) | OB fúziós protein készítmények és módszerek | |
AU750341B2 (en) | Amino-terminally truncated rantes as chemokine antagonists | |
DE10075019I2 (de) | Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung. | |
NZ504752A (en) | Hydrophobically-modified protein compositions (particularly hedgehog proteins) | |
DK0482013T3 (da) | Ikke-glycolyserede humant interleukin-3 analoge proteiner | |
KR980002066A (ko) | 변이형 인간 성장호르몬 및 그의 용도 | |
CA2014948C (en) | Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity | |
KR960014346A (ko) | 개선된 피브린용해 특성 및 트롬빈-억제 활성을 갖는 이작용성 유로키나제 변이체 | |
Jones et al. | Interferon activates macrophages to produce plasminogen activator | |
ES2171563T3 (es) | Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica. | |
ES8205429A1 (es) | Procedimiento para la preparacion de un plasmido que codifica para la secuencia de aminoacidos del interferon de fibro- blastos humanos. | |
HUP9801681A2 (hu) | Mutáns proteinek | |
CA2002833A1 (en) | Interferon-gamma binding proteins | |
WO2002004486A2 (de) | Bifunktionale fusionsproteine aus hirudin und tap | |
KR890014735A (ko) | 변형 단백질 | |
Monet et al. | In vitro relative biological activities of (1--34) N-terminal synthetic fragments of human parathyroid hormone in the human renal cortical adenylate cyclase assay | |
Sachdev et al. | Sequence of cyanogen bromide fragments D and E of B. amyloliquefaciens alpha amylase | |
Koren et al. | Proposal for Classification of Leukocyte‐Associated Cytolytic Molecules: Denver, Colorado, September 28, 1986 | |
Salter et al. | Characterisation of a full-length cDNA clone encoding the pea Rieske Fe-S protein: import and processing by isolated chloroplasts | |
JPS5767592A (en) | Protein having reassociating properties and its preparation | |
Kull Jr et al. | Macrophage cytotoxin: Sources and mechanism | |
MXPA00002881A (en) | Amino-terminally truncated rantes as chemokine antagonists | |
刘建华 et al. | SYNTHESIS AND DETERMINATION OF THE BIOLOGICAL ACTIVITIES OF YEAST ALANINE tRNA ANALOGUES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060818 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |